Jochen Buechner
A5039813382- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- DNA Repair Mechanisms
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- Neuroblastoma Research and Treatments
- CRISPR and Genetic Engineering
- Virus-based gene therapy research
- Chronic Myeloid Leukemia Treatments
- Immunodeficiency and Autoimmune Disorders
- Lymphoma Diagnosis and Treatment
- Carcinogens and Genotoxicity Assessment
- Cancer-related Molecular Pathways
- Signaling Pathways in Disease
- Cancer-related molecular mechanisms research
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer Genomics and Diagnostics
- Polyomavirus and related diseases
- RNA modifications and cancer
- Epigenetics and DNA Methylation
- Mesenchymal stem cell research
- Genomics and Rare Diseases
- Oral health in cancer treatment
- Single-cell and spatial transcriptomics
Oslo University Hospital
2016-2025
Université de Montréal
2018
University Hospital of North Norway
2009-2013
UiT The Arctic University of Norway
2010-2011
University of Freiburg
2003
In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children young adults relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).We conducted 2, single-cohort, 25-center, global study pediatric adult patients CD19+ ALL. The primary end point overall rate (the incomplete hematologic recovery) within 3...
Total body irradiation (TBI) before allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with acute lymphoblastic leukemia (ALL) is efficacious, but long-term side effects are concerning. We investigated whether preparative combination chemotherapy could replace TBI such patients.FORUM a randomized, controlled, open-label, international, multicenter, phase III, noninferiority study. Patients ≤ 18 years at diagnosis, 4-21 HSCT, complete remission pre-HSCT, and an...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. In analysis of global phase II ELIANA trial (ClinicalTrials.gov identifier: NCT02435849), tisagenlecleucel provided...
MicroRNAs (miRNAs) regulate expression of many cancer-related genes through posttranscriptional repression their mRNAs. In this study we investigate the proto-oncogene MYCN as a target for miRNA regulation. A luciferase reporter assay was used to software-predicted sites in 3′-untranslated region (3′UTR) MYCN. The miRNAs were overexpressed cell lines by transfection mimics or miRNA-expressing plasmids. Mutation validate 3′UTR direct several miRNAs. To measure miRNA-mediated suppression...
The inability to generate mesenchymal stromal cells (MSCs) of consistent potency likely is responsible for inconsistent clinical outcomes patients with aGvHD receiving MSC products. We developed a novel manufacturing protocol characterized by high in vitro and near-identity individual doses, referred as "MSC-Frankfurt am Main (MSC-FFM)". Herein, we report the 69 who have received MSC-FFM. These were 51 children 18 adults refractory grade II (4%), III (36%) or IV (59%). Patients either...
We assessed minimal residual disease (MRD) detection and B-cell aplasia after tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers predictive of relapse (N = 143). Next-generation sequencing (NGS) MRD >0 in bone marrow (BM) was highly associated with relapse. recovery [signifying loss functional chimeric antigen receptor (CAR) T cells] within the first year treatment a hazard ratio (HR) 4.5 [95% confidence interval (CI), 2.03-9.97; P < 0.001]. Multivariate...
Not available.
Abstract Background Neuroblastoma is a childhood cancer derived from immature cells of the sympathetic nervous system. The disease clinically heterogeneous, ranging neuronal differentiated benign ganglioneuromas to aggressive metastatic tumours with poor prognosis. Amplification MYCN oncogene well established prognostic factor found in up 40% high risk neuroblastomas. Using neuroblastoma cell lines study differentiation vitro now established. Several protocols, including exposure various...
Abstract Atypical teratoid rhabdoid tumors ( AT / RT ) are characterized by mutations and subsequent inactivation of SMARCB 1 INI 1, hSNF 5 ), a predilection for very young children an unfavorable outcome. The European Registry EU ‐ RHAB was established to generate common database establish standardized treatment regimen as the basis phase I/ II trials. Thus, genetic analyses, neuropathologic radiologic diagnoses, consensus were prospectively evaluated. From 2005 2009, 31 patients with from...
Abstract Although most children with acute lymphoblastic leukemia (ALL) receive fractionated total body irradiation (FTBI) as myeloablative conditioning (MAC) for allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is an important matter of debate if chemotherapy can effectively replace FTBI. To compare outcomes after FTBI versus chemotherapy-based (CC), we performed a retrospective EBMT registry study. Children aged 2–18 years MAC first allo-HSCT bone marrow (BM) or...
Background Tisagenlecleucel, an anti-CD19 chimeric antigen receptor T cell therapy, has demonstrated efficacy in children and young adults with relapsed/refractory B acute lymphoblastic leukemia (B-ALL) two multicenter phase 2 trials (ClinicalTrials.gov, NCT02435849 (ELIANA) NCT02228096 (ENSIGN)), leading to commercialization of tisagenlecleucel for the treatment patients up age 25 years B-ALL that is refractory or second greater relapse. Methods A pooled analysis 137 from these (ELIANA:...
Abstract Cytokine release syndrome (CRS) is a systemic inflammatory response associated with chimeric antigen receptor T-cell (CAR-T) therapies. In severe cases, CRS can be coagulopathy and hypofibrinogenemia. We present our global multicenter experience CRS-associated after tisagenlecleucel therapy in 137 patients relapsed or refractory B-cell acute lymphoblastic leukemia from the ELIANA ENSIGN trials. These trials included clinical guidelines for fibrinogen replacement during coagulopathy....
The MYCN oncogene is frequently amplified in neuroblastoma. It one of the most consistent markers bad prognosis for this disease. Dickkopf-3 (DKK3) a secreted protein DKK family Wnt regulators. functions as tumor suppressor range cancers, including was recently found to downregulate DKK3 mRNA. In study, we show that knockdown MYCN-amplified (MNA) neuroblastoma cell lines increases secretion endogenous culture media. MicroRNAs (miRNAs) are ∼20 nt long single-stranded RNA molecules messenger...
We performed molecular, enzyme, and metabolic studies in 50 patients with D-2-hydroxyglutaric aciduria (D-2-HGA) who accumulated D-2-hydroxyglutarate (D-2-HG) physiological fluids. Presumed pathogenic mutations were detected 24 of the dehydrogenase (D2HGDH) gene, which encodes (D-2-HGDH). Enzyme assay D-2-HGDH confirmed that all had impaired enzyme activity, whereas D-2-HGA whose activity was normal did not have mutations. Significantly lower D-2-HG concentrations body fluids observed...
(1) Background: Refractory acute graft-versus-host disease (R-aGvHD) remains a leading cause of death after allogeneic stem cell transplantation. Survival rates 15% four years are currently achieved; deaths only in part due to aGvHD itself, but mostly adverse effects R-aGvHD treatment with immunosuppressive agents as these predispose patients opportunistic infections and loss graft-versus-leukemia surveillance resulting relapse. Mesenchymal stromal cells (MSC) from different tissues those...